Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Update

Aileron Therapeutics, Inc. (NASDAQ:ALRN) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 35,300 shares, an increase of 7.0% from the March 15th total of 33,000 shares. Approximately 0.9% of the company’s shares are short sold. Based on an average daily trading volume, of 39,200 shares, the short-interest ratio is currently 0.9 days.

Institutional Trading of Aileron Therapeutics

A number of hedge funds have recently added to or reduced their stakes in ALRN. Renaissance Technologies LLC boosted its stake in Aileron Therapeutics by 96.9% in the 2nd quarter. Renaissance Technologies LLC now owns 115,191 shares of the company’s stock worth $30,000 after buying an additional 56,691 shares during the last quarter. Envestnet Asset Management Inc. raised its holdings in shares of Aileron Therapeutics by 52.9% in the 3rd quarter. Envestnet Asset Management Inc. now owns 184,022 shares of the company’s stock worth $38,000 after purchasing an additional 63,651 shares during the period. Texas Capital Bank Wealth Management Services Inc purchased a new position in shares of Aileron Therapeutics in the 4th quarter worth about $48,000. Sigma Planning Corp purchased a new position in shares of Aileron Therapeutics in the 4th quarter worth about $51,000. Finally, Geode Capital Management LLC raised its holdings in shares of Aileron Therapeutics by 23.2% in the 1st quarter. Geode Capital Management LLC now owns 54,799 shares of the company’s stock worth $68,000 after purchasing an additional 10,311 shares during the period. 90.89% of the stock is owned by institutional investors and hedge funds.

Aileron Therapeutics Price Performance

Shares of NASDAQ:ALRN opened at $5.93 on Tuesday. The stock’s 50-day moving average price is $5.38 and its two-hundred day moving average price is $3.55. Aileron Therapeutics has a 12-month low of $1.01 and a 12-month high of $7.12.

About Aileron Therapeutics

Aileron Therapeutics, Inc operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial.